June 2008 Volume 4 Issue 4

Organic CHEMISTRY

Trade Science Inc.

An Indian Journal

FUII Paper

OCAIJ, 4(4), 2008 [309-313]

A convenient methodology for the synthesis of functionalized nitrogen mustards

A.V.Reddy¹, J.Gopalakrishna¹, Kelley T.Kovich¹, Subash C.Jonnalagadda^{2*}, Venkatram R.Mereddy^{1*} ¹Department of Chemistry and Biochemistry, University of Minnesota Duluth, 1039 University Drive, Duluth, MN 55812, (U.S.A)

²Department of Chemistry and Biochemistry, Rowan University, 201 Mullica Hill Road, Glassboro, NJ 08028, (U.S.A)

E-mail: vmereddy@d.umn.edu

Received: 1st June, 2008; Accepted: 6th June, 2008

KEYWORDS ABSTRACT

A short protocol for the synthesis of functionalized bis(chloroethyl)amines (nitrogen mustards) has been described via the nucleophilic substitution of allylic bromides derived from Baylis-Hillman alcohols with diethanolamine followed by dichlorination. © 2008 Trade Science Inc. - INDIA

Baylis hillman reaction; Bis(chloroethyl)amines; Nitrogen mustards; Chlorethamine drugs; Nucleophilic substitution.

INTRODUCTION

Bis(chloroethyl) amine moiety is an excellent pharmacophore in nitrogen mustard based DNA alkylating anticancer agents^[1]. The reaction mechanism of these molecules involves the formation of reactive aziridinium intermediate followed by a nucleophilic attack of the DNA to form mono and dialkylated DNA adducts resulting in the cellular toxicity (Figure 1)[2].




Figure 1: General mode of anti-cancer action of nitrogen mustards

There are several chloroethylamine based drugs that are in clinical use for the treatment of wide variety of cancers. Some of these include mechlorethamine (1) (used for Hodgkin's disease, chronic myelocytic/chronic lymphocytic leukemia (CLL), lymphosarcoma, and lung cancer), chlorambucil (2) (for CLL and malignant lymphomas including giant follicular lymphoma, lymphosarcoma, and Hodgkin's disease), melphalan 3 (for multiple myeloma, breast and ovarian cancer), cyclophosm amide (4) (for breast, ovarian, lymphomas, leukemia's, multiple myloema, lung, and bone), ifosfamide (5) (for testicular, bone and lung cancers, soft tissue sarcoma,) etc. (Figure 2)^[1].

EXPERIMENTAL

Preparation of diol (13a)

To a suspension of Na₂CO₂ (2.12 g, 20.0 mmol) in CH₂CN (20.0 mL) was added diethanolamine (1.05 g, 10.0 mmol) and the bromide (11a) (2.55 g, 10.0

Full Paper

Figure 2: Anti-cancer nitrogen mustards in clinical use

mmol) and heated at 60°C for 3h. Upon complete consumption of the bromide, the reaction mixture was filtered and washed with dichloromethane. The filtrate was concentrated and purified by silica gel column chromatography (dichloromethane:methanol, 10:1) to obtain 2.0 g (72%) of the pure diol. (~5% of SN₂' susbstitution product was also observed). ¹H NMR (500 MHz, CDCl₃): δ 7.86 (s, 1H), 7.32-7.45 (m, 5H), 3.85 (s, 3H), 3.62 (s, 2H), 3.58 (t, J = 5.5 Hz, 4H), 2.55 (t, J = 5.5 Hz, 4H); ¹³C NMR (125 MHz, CDCl₃): δ 169.2, 142.6, 135.1, 131.1, 129.5, 129.0, 128.8, 59.6, 55.7, 52.6, 49.6; ESI-MS: 280 (M+H)⁺.

Preparation of diol (13b)

Procedure similar to that of **(13a)**. ¹H NMR (500 MHz, CDCl₃): δ 7.83 (s, 1H), 7.20-7.30 (m, 4H), 3.85 (s, 3H), 3.66 (t, J = 5.5 Hz, 4H), 3.60 (t, J = 5.5 Hz, 4H), 2.98 (br s, 2H), 2.56 (m, 4H), 2.4 (s, 3H); ¹³C NMR (125 MHz, CDCl₃): δ 169.4, 142.9, 139.3, 132.1, 130.1, 129.7, 129.5, 58.6, 55.6, 52.6, 49.6, 21.6; ESI-MS: 294 [(M+H)⁺, 100%]

Preparation of diol (13c)

Procedure similar to that of (**13a**). ¹H NMR (500 MHz, CDCl₃): δ 7.74 (s, 1H), 7.30-7.36 (m, 4H), 3.81 (s, 3H), 3.56 (t, J = 5.5 Hz, 4H), 3.17 (br s, 2H), 2.52 (t, J = 5.5 Hz, 4H); ¹³C NMR (125 MHz, CDCl₃): 169.0, 141.2, 133.5, 131.0, 129.0, 59.6, 55.7, 52.6, 49.5; ESI-MS: 314 [(M+H)⁺, 100%]

Preparation of diol (13d)

Procedure similar to that of (**13a**). ¹H NMR (500 MHz, CDCl₃): δ 7.59 (d, J = 8.5 Hz, 2H), 7.33 (d, J = 8.5 Hz, 2H), 6.38 (s, 1H), 5.45 (s, 1H), 5.11 (s, 1H), 3.45-3.63 (m, 4H), 2.63-2.91 (m, 4H); ¹³C NMR (125 MHz, CDCl₃): δ 168.1, 143.3, 140.7, 132.6, 130.2, 129.2, 118.8, 111.8, 64.3, 60.5, 53.0, 52.8; ESI-MS: 305 [(M+H)⁺, 100%]

Preparation of diol (13e)

Procedure similar to that of **(13a)**. ¹H NMR (500MHz, CDCl₃): δ 6.22 (d, J = 1.0 Hz, 1H), 5.75 (d, J = 1.5 Hz, 1H), 3.74 (s, 3H), 3.58 (t, J = 6.0 Hz, 4H), 3.32 (m, 3H), 2.62 (t, J = 6.0 Hz, 4H); ¹³C NMR (125 MHz, CDCl₃): δ 167.8, 137.9, 128.4, 59.6, 55.7, 55.6, 52.3.

Preparation of diol (13f)

Procedure similar to that of (**13a**). ¹H NMR (500MHz, CDCl₃): 7.81 (s, 1H), 7.22-7.44 (m, 5H), 4.23 (t, J = 7.5 Hz, 2H), 3.62 (s, 2H), 3.58 (t, J = 7.5 Hz, 4H), 2.54 (t, J = 7.5 Hz, 4H), 1.64-1.76 (m, 2H), 1.16-1.48 (m, 26H), 0.87 (t, J = 7.5 Hz, 3H).

Preparation of bis(chloroethyl) amine (14a)

To a solution of the diol (13a) (1.39 g, 5.0 mmol) in 10.0 mL of CH_2Cl_2 at 0°C was added excess thionyl chloride (7.1 mL, 100.0 mmol) over a period of 20 minutes and stirred for 2h. Upon completion (TLC), the reaction mixture was quenched by the addition of methanol (10mL) and concentrated in vacuo. The crude product thus obtained was purified by silica gel column chromatography (hexane: ethyl acetate, 4:1) to obtain 1.18 g (75%) of bis(chloroethyl) amine (14a). ¹H NMR (500 MHz, CDCl₃): δ 7.85 (s, 1H), 7.28-7.54 (m, 5H), 3.87 (s, 3H), 3.62 (s, 2H), 3.49 (t, J = 7.0 Hz, 4H), 2.87 (t, J = 7.0 Hz, 4H); ¹³C NMR (125 MHz, CDCl₃): δ 169.0, 142.9, 135.2, 130.5, 130.0, 129.2, 128.8, 56.2, 52.4, 50.2, 41.8.

Preparation of bis(chloroethyl) amine (14a)

To a solution of the diol (13a) (1.39 g, 5.0 mmol) in 10.0 mL of CH₂Cl₂ at 0°C was added excess thionyl chloride (7.1 mL, 100.0 mmol) over a period of 20 minutes and stirred for 2h. Upon completion (TLC), the reaction mixture was quenched by the addition of methanol (10mL) and concentrated in vacuo. The crude

Full Paper

product thus obtained was purified by silica gel column chromatography (hexane: ethyl acetate, 4:1) to obtain 1.18g (75%) of bis(chloroethyl) amine (**14a**). ¹H NMR (500 MHz, CDCl₃): δ 7.85 (s, 1H), 7.28-7.54 (m, 5H), 3.87 (s, 3H), 3.62 (s, 2H), 3.49 (t, J = 7.0 Hz, 4H), 2.87 (t, J = 7.0 Hz, 4H); ¹³C NMR (125 MHz, CDCl₃): δ 169.0, 142.9, 135.2, 130.5, 130.0, 129.2, 128.8, 56.2, 52.4, 50.2, 41.8.

Preparation of bis(chloroethyl) amine (14b)

Procedure similar to that of (**14a**). ¹H NMR (500 MHz, CDCl₃): δ 7.84 (s, 1H), 7.47 (d, J = 8.0 Hz, 2H), 7.23 (d, J = 8.0 Hz, 2H), 3.85 (s, 3H), 3.63 (s, 2H), 3.50 (t, J = 7.0 Hz, 4H), 2.88 (t, J = 7.2 Hz, 4H), 2.40 (s, 3H); ¹³C NMR (125 MHz, CDCl₃): δ 169.2, 143.3, 139.6, 132.3, 130.3, 129.5, 129.4, 56.2, 52.4, 50.4, 41.9, 21.6.

Preparation of bis(chloroethyl) amine (14c)

Procedure similar to that of (**14a**). ¹H NMR (500 MHz,CDCl₃): δ 7.80 (s, 1H), 7.55 (d, J = 8.5 Hz, 2H), 7.39 (d, J = 8.5 Hz, 2H), 3.85 (s, 3H), 3.59 (s, 2H), 3.51 (t, J = 7.0 Hz, 4H), 2.87 (t, J = 7.0 Hz, 4H); ¹³C NMR (125 MHz, CDCl₃): δ 168.8, 142.1, 135.5, 133.5, 131.7. 130.6, 129.1, 56.0, 52.6, 50.4, 41.8.

Preparation of bis(chloroethyl) amine (14d)

Procedure similar to that of (**14a**). ¹H NMR (500 MHz, CDCl₃): δ 7.82 (s, 1H), 7.72 (m, 4H), 3.88 (s, 3H), 3.58 (s, 2H), 3.51 (t, J = 6.5 Hz, 4H), 2.87 (t, J = 6.5 Hz, 4H); ¹³C NMR (125 MHz, CDCl₃): δ 168.4, 140.9, 139.6, 132.9, 132.5, 130.7, 118.7, 112.8, 55.9, 52.7, 50.4, 41.7. ESI-MS: 337 [(M-CN+Na)⁺, 100%].

Preparation of bis(chloroethyl) amine (14e)

Procedure similar to that of (**14a**). ¹H NMR (500 MHz, CDCl₃): δ 6.22 (d, J = 1.5 Hz, 1H), 5.84 (d, J = 1.5 Hz, 1H), 3.75 (s, 3H), 3.50 (t, J = 7.0 Hz, 4H), 3.42 (s, 2H), 2.91 (t, J = 7.0 Hz, 4H), ¹³C NMR (125 MHz, CDCl₃): δ 167.3, 138.2, 126.8, 56.6, 55.7, 52.1, 42.0.

Preparation of bis(chloroethyl) amine (14f)

Procedure similar to that of (**14a**). 1 H NMR (500 MHz, CDCl₃): 7.71 (s, 1H), 7.24-7.42 (m, 5H), 4.12 (t, J = 7.0 Hz, 2H), 3.52 (s, 2H), 3.35 (t, J = 7.0 Hz, 4H), 2.75 (t, J = 7.0 Hz, 4H)1.61-1.64 (m, 2H), 1.10-1.38 (m, 26H), 0.78 (t, J = 7.5 Hz, 3H); 13 C NMR (125

MHz, CDCl₃): δ 168.6, 142.8, 135.3, 130.7, 130.0, 129.2, 128.7, 65.6, 56.2, 50.3, 41.8, 32.2, 29.96, 29.95, 29.93, 29.87, 29.82, 29.6, 29.5, 29.0, 26.3, 22.9, 14.4.

Preparation of hydrochloride (15a)

To a solution of the bis(chloroethyl) amine (**14a**) (1.0 g, 3.16 mmol) in ether (10 mL), was added 4.0 mL of HCl (1M solution in ether) and stirred for an hour. The resulting solid was filtered and dried in vacuo to obtain the hydrochloride salt (**15a**) in 90% yield (1.0 g). ¹H NMR (500 MHz, CDCl₃): δ 8.30 (s, 1H), 7.39-7.54 (m, 5H), 4.39 (s, 2H), 3.97 (s, 3H), 3.86 (m, 4H), 3.38 (m, 4H); 13C NMR (125 MHz, CDCl₃): 166.9, 150.1, 133.3, 130.7, 129.9, 129.0, 122,6, 55.2, 53.6, 49.2, 37.0; ESI-MS: 316 [(M-Cl)⁺, 100%], 318 [(M+2-Cl)⁺, 67%].

Preparation of hydrochloride (15b)

Procedure similar to that of **(15a)**. 1 H NMR (500 MHz, CDCl₃): δ 8.25 (s, 1H), 7.28-7.34 (m, 4H), 4.46 (s, 2H), 3.95 (s, 3H), 3.90 (s, 4H), 3.46 (s, 4H), 2.40 (s, 3H); 13 C NMR (500 MHz, CDCl₃): 167.1, 150.4, 141.5, 130.6, 130.2, 129.5, 129.4, 55.3, 53.5, 49.5, 37.1, 21.7; ESI-MS: 330 [(M-Cl)⁺, 100%], 332 [(M+2-Cl)⁺, 67%].

Preparation of hydrochloride (15d)

Procedure similar to that of **(15a)**. ¹H NMR (500 MHz, CDCl₃): δ 8.11 (s, 1H), 7.79 (m, 2H), 7.67 (m, 2H), 4.15 (br s, 2H), 3.96 (s, 3H), 3.80 (m, 4H), 3.32 (m, 4H); ¹³C NMR (125 MHz, CDCl₃): δ 167.1, 145.4, 138.2, 133.2, 130.4, 118.3, 113.8, 55.7, 53.5, 50.3, 38.8; ESI-MS: 341 [(M-Cl)⁺, 100%], 343 [(M+2-Cl)⁺, 67%].

Preparation of hydrochloride (15f)

Procedure similar to that of **(15a)**. ¹H NMR (500 MHz, CDCl₃): δ 8.28 (b, 1H), 7.43-7.57 (m, 5H), 4.47 (s, 2H), 4.36 (t, J = 7.5 Hz, 2H), 3.83-3.92 (m, 4H), 3.48-3.52 (m, 4H), 1.76-1.84 (m, 2H), 1.24-1.42 (m, 26H), 0.90 (t, J = 7.0 Hz, 3H); ¹³C NMR (125 MHz, CDCl₃): δ 166.9, 150.2, 133.0, 130.8, 129.9, 129.3, 121.9, 67.1, 66.1, 55.4, 49.5, 37.1, 32.1, 29.93, 29.92, 29.89, 29.84, 29.76, 29.6, 29.5, 28.8, 26.2, 22.9, 15.5, 14.4.

Full Paper

RESULTS AND DISCUSSION

Baylis-Hillman reaction is an important C-C bond forming reaction and it offers densely functionalized alcohols and amines in one step $^{[3]}$. The reaction is highly atom efficient, compatible with wide variety of functional groups and the reaction does not require any organic solvents, thus making it environmentally benign. The product allylic alcohols undergo facile isomerization with a variety of nucleophiles in SN_2 ' fashion to afford valuable synthetic intermediates.

We envisaged that $\mathrm{SN_2}$ ' type isomerization of Baylis-Hillman acetates or $\mathrm{SN_2}$ substitution of Baylis-Hillman bromides with diethanolamine followed by chlorination of the resulting diols would provide an easy access to functionalized bis(chloroethyl)amines (nitrogen mustards) with high tunability for further structural modifications.

We initiated the synthesis via the Baylis Hillman reaction of benzaldehyde with methyl acrylate in the presence of DABCO to obtain the allylic alcohol (9) that upon acetylation afforded the acetate (10). Initial efforts towards the nucleophilic substitution of acetate with bis(2-chloroethyl)amine failed under a variety of conditions. Changing the base, temperature, and solvents also did not effect the formation of the product

SCHEME 1: Attempted SN_2 ' substitution of baylis-hillman acetates

cleanly. Substitution of the acetate with diethanolamine also proved futile and no product formation was observed (SCHEME 1).


We then attempted the substitution of the allylic bromide (11) obtained by the reaction of alcohol (9) with HBr and H₂SO₄^[4]. The direct reaction of bis (chloroethyl) amine with bromide (11) also did not provide the product. Finally, the substitution was realized by the reaction of diethanolamine (12) with (11) in the presence of Na₂CO₂. The reaction at ambient temperature was observed to be relatively slow and lower yields of the corresponding diol (13) were obtained. Heating the reaction at 60°C in CH₂CN accelerated the product formation and the reaction was complete within 2 hours. Reaction of the diol with excess thionyl chloride^[5] resulted in the clean formation of bis(chloroethyl) amine (14). To increase the hydrophilicity of (14), the corresponding hydrochloride salt (15) was prepared by treatment with hydrogen chloride solution in anhydrous ether (SCHEME 2).

To demonstrate the applicability of the protocol,

TABLE 1: Synthesis of functionalized bis(chloroethyl) amines

Sr.	$\mathbf{R_1}$	\mathbf{R}_2	Diola		Dichloride		Hydrochloride	
			Compd.	Yld (%)	Compd.	Yld (%)	Compd.	Yld (%)
1	Ph	Me	13a	72	14a	75	15a	90
2	4-MePh	Me	13b	73	14b	73	15b	92
4	4-ClPh	Me	13c	69	14c	76	15c	89
5	4-CNPh	Me	13d	74	14d	75	15d	94
6	Н	Me	13e	75	14e	70	15e	88
7	Ph	$C_{16}H_{33}$	13f	71	14f	76	15f	90

^a5-10% of SN,' substitution product was also observed



SCHEME 2: Synthesis of functionalized bis(chloroethyl) amines

- Full Paper

REFERENCES

various functionalized nitrogen mustards (14a-g) and their hydrochloride salts (15a-g) were prepared via SN_2 -substitution-halogenation procedure. The requisite allylic bromides (11a-g) were prepared by the reaction of corresponding aldheydes with methyl acrylate followed by treatment with HBr. The reaction of diethanolamine with the bromides (11a-g) yielded the diols (13a-g) in 69-76% yields. Thionyl chloride treatment yielded the dichlorides (14a-g) which were further converted to the hydrochlorides (15a-g) in good yields (TABLE 1). Studies are underway to determine the efficacy of these molecules as anti-cancer agents.

CONCLUSIONS

In conclusion, we have synthesized several functionalized bis(chloroethyl)amine (nitrogen mustard) small molecules as potential anticancer agents. The Baylis-Hillman template provides various possibilities for structural modifications as well as opportunities for linking with biologically relevant carrier molecules for targeted delivery. Owing to the significance of Baylis-Hillman reaction, ease of functionalization, high flexibility, and the importance of nitrogen mustards as cancer chemotherapeutics, the present study could be applied to obtain novel DNA alkylating agents for cancer treatment.

ACKNOWLEDGMENT

We thank University of Minnesota Duluth and Rowan University for the facilities and funding.

- 1] (a) D.M.Noll, T.M.Mason, P.S.Miller; Chem.Rev., **106**, 277 (**2006**).
 - (**b**) L.P.Bignold; Anticancer Research, **26**, 1327 (**2006**).
 - (c) W.A.Denny; Current Med.Chem., **8**, 533 (**2001**).
- [2] P.Brooks, P.D.Lawley; Biochem.J., **80**, 496 (**1961**).
- [3] (a) D.Basavaiah, K.V.Rao, R.J.Reddy; Chem.Soc. Rev., 36, 1581 (2007).
 - **(b)** D.Basavaiah, A. J.Rao, T.Satyanarayana; Chem. Rev., **103**, 811 **(2003)**.
 - (c) E.Ciganek; 'Organic Reactions', John Wiley, New York, **51**, 201 (**1997**).
 - (d) D.Basavaiah, P.D.Rao, R.S.Hyma; Tetrahedron, **52**, 8001 (**1996**).
- [4] (a) L.Fernandes, A.J.Bortoluzzi, M.M.Sa; Tetra hedron, 60, 9983 (2004).
 - (**b**) R.Buchholz, H.M.R.Hoffman, Helv.Chim.Acta, **74**, 1213 (**1991**).
- [5] P.M.Kushakova, A.N.Chernobroviy, V.A.Kuznetsov, A.V.Garabadgiu; Chem.Heterocyclic Compounds, 40, 1546 (2004).